Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

Scientific Presentation at British Neuro-Oncology Annual Meeting Shows Original Analysis of Survival Extension Was Likely UnderestimatedBETHESDA, Md., July 8, 2026 /PRNewswire/ -- Northwest Biothe...